Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06880770 · ClinicalTrials.gov registry record · Phase 3

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

A Phase 3 study of Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
288
Enrollment target
20
Study locations

NCT06880770 is a Phase 3 study of Severe Hypertriglyceridemia that is actively recruiting participants, run by Arrowhead Pharmaceuticals. The registered enrollment target is 288 participants, below the 389-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06880770, a Phase 3 study of Severe Hypertriglyceridemia, is actively recruiting participants, sponsored by Arrowhead Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
288 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.

Conditions Studied

Severe Hypertriglyceridemia

Interventions

  • DRUG Placebo
  • DRUG Plozasiran

Study Locations (20)

Minas Gerais

  • Research Site - Belo Horizonte
  • Research Site - Belo Horizonte
  • Research Site - Belo Horizonte

California

  • Research Site - Los Angeles
  • Clinical Research Site 4 - Santa Clarita

North Carolina

  • Clinical Research Site 3 - Greensboro
  • Research Site - Wilmington

Texas

  • Clinical Research Site 1 - Mesquite
  • Clinical Research Site 2 - San Antonio

Other

  • Research Site - Graz
  • Research Site - Burgas

Rio Grande do Sul

  • Research Site - Porto Alegre
  • Research Site - Pôrto Alegre

Illinois

  • Clinical Research Site 6 - Springfield

Indiana

  • Research Site - Indianapolis

Trial Details

FieldValue
Enrollment Target 288 participants
Start Date 2025-04-24
Est. Completion 2029-06
Phase Phase 3

Sponsor

Arrowhead Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06880770

The ClinicalTrials.gov registry entry for NCT06880770 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 389-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (26% lower). The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06880770 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Minas Gerais, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06880770 about?

NCT06880770 is a clinical study titled "Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis". This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months pr...

What is the current status of trial NCT06880770?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2025-04-24. Estimated completion is 2029-06.

What conditions does trial NCT06880770 study?

This clinical trial studies the following conditions: Severe Hypertriglyceridemia.

What interventions are being tested in trial NCT06880770?

The interventions under investigation include: Placebo (DRUG), Plozasiran (DRUG).

Who is sponsoring clinical trial NCT06880770?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06880770 being conducted?

This trial has 20 study locations across California, Illinois, Indiana, Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Severe Hypertriglyceridemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.